Form 8-K - Current report:
SEC Accession No. 0001628280-23-010022
Filing Date
2023-03-31
Accepted
2023-03-31 07:50:02
Documents
14
Period of Report
2023-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bvs-20230331.htm   iXBRL 8-K 34594
2 EX-99.1 bioventusex-991q42022.htm EX-99.1 501484
6 image_0.jpg GRAPHIC 50612
  Complete submission text file 0001628280-23-010022.txt   779966

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bvs-20230331.xsd EX-101.SCH 1902
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bvs-20230331_lab.xml EX-101.LAB 25848
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bvs-20230331_pre.xml EX-101.PRE 13582
8 EXTRACTED XBRL INSTANCE DOCUMENT bvs-20230331_htm.xml XML 4748
Mailing Address 4721 EMPEROR BOULEVARD, SUITE 100 DURHAM NC 27703
Business Address 4721 EMPEROR BOULEVARD, SUITE 100 DURHAM NC 27703 (919) 474-6700
Bioventus Inc. (Filer) CIK: 0001665988 (see all company filings)

EIN.: 810980861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37844 | Film No.: 23783277
SIC: 3841 Surgical & Medical Instruments & Apparatus